IMCR PE Ratio & Valuation,Is IMCR Overvalued

IMCR Relative Valuation

IMCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMCR is overvalued; if below, it's undervalued.

Historical Valuation

Immunocore Holdings PLC (IMCR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -45.50. The fair price of Immunocore Holdings PLC (IMCR) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：36.02

Fair

-73.45

-26.50

EV/EBITDA

Immunocore Holdings PLC. (IMCR) has a current EV/EBITDA of -26.50. The 5-year average EV/EBITDA is -57.20. The thresholds are as follows: Strongly Undervalued below -332.60, Undervalued between -332.60 and -194.90, Fairly Valued between 80.50 and -194.90, Overvalued between 80.50 and 218.19, and Strongly Overvalued above 218.19. The current Forward EV/EBITDA of -26.50 falls within the Historic Trend Line -Fairly Valued range.

-31.88

EV/EBIT

Immunocore Holdings PLC. (IMCR) has a current EV/EBIT of -31.88. The 5-year average EV/EBIT is -26.87. The thresholds are as follows: Strongly Undervalued below -71.79, Undervalued between -71.79 and -49.33, Fairly Valued between -4.41 and -49.33, Overvalued between -4.41 and 18.05, and Strongly Overvalued above 18.05. The current Forward EV/EBIT of -31.88 falls within the Historic Trend Line -Fairly Valued range.

4.18

Immunocore Holdings PLC. (IMCR) has a current PS of 4.18. The 5-year average PS is 15.49. The thresholds are as follows: Strongly Undervalued below -15.81, Undervalued between -15.81 and -0.16, Fairly Valued between 31.14 and -0.16, Overvalued between 31.14 and 46.79, and Strongly Overvalued above 46.79. The current Forward PS of 4.18 falls within the Historic Trend Line -Fairly Valued range.

-306.94

P/OCF

Immunocore Holdings PLC. (IMCR) has a current P/OCF of -306.94. The 5-year average P/OCF is -180.82. The thresholds are as follows: Strongly Undervalued below -1431.41, Undervalued between -1431.41 and -806.11, Fairly Valued between 444.47 and -806.11, Overvalued between 444.47 and 1069.76, and Strongly Overvalued above 1069.76. The current Forward P/OCF of -306.94 falls within the Historic Trend Line -Fairly Valued range.

-3541.94

P/FCF

Immunocore Holdings PLC. (IMCR) has a current P/FCF of -3541.94. The 5-year average P/FCF is -252.30. The thresholds are as follows: Strongly Undervalued below -1713.39, Undervalued between -1713.39 and -982.85, Fairly Valued between 478.24 and -982.85, Overvalued between 478.24 and 1208.78, and Strongly Overvalued above 1208.78. The current Forward P/FCF of -3541.94 falls within the Strongly Undervalued range.

Immunocore Holdings PLC (IMCR) has a current Price-to-Book (P/B) ratio of 4.58. Compared to its 3-year average P/B ratio of 6.25 , the current P/B ratio is approximately -26.76% higher. Relative to its 5-year average P/B ratio of 6.18, the current P/B ratio is about -25.89% higher. Immunocore Holdings PLC (IMCR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.33%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -2.54% , the current FCF yield is about -100.00% lower.

4.58

P/B

Median3y

6.25

Median5y

6.18

0.16

FCF Yield

Median3y

0.33

Median5y

-2.54

Competitors Valuation Multiple

The average P/S ratio for IMCR's competitors is , providing a benchmark for relative valuation. Immunocore Holdings PLC Corp (IMCR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 29.22%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IMCR increased by 22.10% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -31.77 to -61.78.

The secondary factor is the Revenue Growth, contributed 29.22%to the performance.

Overall, the performance of IMCR in the past 1 year is driven by P/E Change. Which is more unsustainable.

29.22%

80.25M → 103.69M

Revenue Growth

-101.56%

10.89 → -0.17

Margin Expansion

94.44%

-31.77 → -61.78

P/E Change

22.10%

29.50 → 36.02

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Immunocore Holdings PLC (IMCR) currently overvalued or undervalued?

What is Immunocore Holdings PLC (IMCR) fair value?

IMCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immunocore Holdings PLC (IMCR) is between NaN to NaN according to relative valuation methord.

How does IMCR's valuation metrics compare to the industry average?

What is the current P/B ratio for Immunocore Holdings PLC (IMCR) as of Dec 16 2025?

As of Dec 16 2025, Immunocore Holdings PLC (IMCR) has a P/B ratio of 4.58. This indicates that the market values IMCR at 4.58 times its book value.

What is the current FCF Yield for Immunocore Holdings PLC (IMCR) as of Dec 16 2025?

As of Dec 16 2025, Immunocore Holdings PLC (IMCR) has a FCF Yield of 0.00%. This means that for every dollar of Immunocore Holdings PLC’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Immunocore Holdings PLC (IMCR) as of Dec 16 2025?

As of Dec 16 2025, Immunocore Holdings PLC (IMCR) has a Forward P/E ratio of -73.45. This means the market is willing to pay $-73.45 for every dollar of Immunocore Holdings PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Immunocore Holdings PLC (IMCR) as of Dec 16 2025?

As of Dec 16 2025, Immunocore Holdings PLC (IMCR) has a Forward P/S ratio of 0.00. This means the market is valuing IMCR at $0.00 for every dollar of expected revenue over the next 12 months.

IMCR Valuation